Form 8-K

8-K — Acadia Healthcare Company, Inc.

Accession: 0001437749-26-024693

Filed: 2026-07-28

Period: 2026-07-28

CIK: 0001520697

SIC: 8093 (SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — achc20260728c_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex_994474.htm)

EX-99.2 — EXHIBIT 99.2 (ex_994475_source.htm)

GRAPHIC (a01.jpg)

GRAPHIC (a02.jpg)

GRAPHIC (a03.jpg)

GRAPHIC (a04.jpg)

GRAPHIC (a05.jpg)

GRAPHIC (a06.jpg)

GRAPHIC (a07.jpg)

GRAPHIC (a08.jpg)

GRAPHIC (a09.jpg)

GRAPHIC (a10.jpg)

GRAPHIC (a11.jpg)

GRAPHIC (a12.jpg)

GRAPHIC (a13.jpg)

GRAPHIC (a14.jpg)

GRAPHIC (a15.jpg)

GRAPHIC (a16.jpg)

GRAPHIC (a17.jpg)

GRAPHIC (a18.jpg)

GRAPHIC (a19.jpg)

GRAPHIC (a20.jpg)

GRAPHIC (a21.jpg)

GRAPHIC (acadialogo01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: achc20260728c_8k.htm · Sequence: 1

achc20260728c_8k.htm

false

0001520697

2026-07-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 28, 2026 (July 28, 2026)

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-35331

45-2492228

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4020 Aspen Grove Drive, Suite 900

Franklin, Tennessee

(Address of Principal Executive Offices)

37067

(Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ACHC

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 28, 2026, Acadia Healthcare Company, Inc. (the “Company”) issued a press release announcing, among other things, the Company’s operating and financial results for the second quarter ended June 30, 2026. The press release is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The Company will conduct a conference call to discuss its second quarter 2026 financial results on Wednesday, July 29, 2026 at 9:00 a.m. Eastern Time. In discussing the Company’s results, Company representatives may refer to information described on the slides furnished with this Current Report on Form 8-K as Exhibit 99.2 hereto. The live broadcast of the conference call and the slides will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. The webcast of the conference call will be available on the Company’s website for thirty days.

The information furnished pursuant to Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including the information in Exhibit 99.1 and Exhibit 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibits furnished herewith contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements related to the Company’s strategy, growth and anticipated operating results for future periods. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this report. The Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties, and the Company’s future results could differ significantly from those expressed or implied by its forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of facility expansions, acquisitions, joint ventures and de novo transactions; (ii) the Company’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by the Company from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (the “OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of the Company’s common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that the Company may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) changes in expectations resulting from actuarial and other reviews of the Company’s liability reserves and other aspects of its business; (vii) potential disruptions to the Company’s information technology systems or adverse impacts of a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to the OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent the Company from realizing the expected benefits of its business strategies. These factors and others are more fully described in the Company’s periodic reports and other filings with the Securities and Exchange Commission.

Description of Business

Unless the context otherwise requires, all references herein to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries own and operate acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the U.S. and Puerto Rico. The terms “facilities,” “centers,” “clinics” and “hospitals” refer to entities owned, operated or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to “employees” refer to employees of subsidiaries of Acadia Healthcare Company, Inc.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

99.1

Press Release of Acadia Healthcare Company, Inc., dated July 28, 2026.

99.2

Slide Presentation, dated July 28, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA HEALTHCARE COMPANY, INC.

Date: July 28, 2026

By:

/s/ David Duckworth

David Duckworth

Interim Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex_994474.htm · Sequence: 2

ex_994474.htm

Exhibit 99.1

ACADIA HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS AND UPDATES FULL YEAR 2026 FINANCIAL AND CASH FLOW GUIDANCE

FRANKLIN, Tenn. (July 28, 2026) – Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Results

●

Revenue totaled $865.8 million, which was approximately flat compared with the second quarter of 2025. As described on page 2, total revenue growth in the second quarter was 2.8% after normalizing for prior period supplemental payment program revenue in each of the respective quarters.

●

Same-facility revenue was flat compared with the second quarter of 2025, as patient days increased 0.8% and revenue per patient day decreased 0.8%

●

Net income attributable to Acadia totaled $10.9 million, or $0.12 per diluted share, compared with $30.1 million, or $0.33 per diluted share, in the prior-year period

●

Adjusted net income attributable to Acadia totaled $35.1 million, or $0.38 per diluted share, compared with $74.8 million, or $0.83 per diluted share, in the prior-year period

●

Adjusted EBITDA was $149.2 million, compared with $201.8 million in the prior-year period. Second quarter 2026 Adjusted EBITDA includes a $28.6 million adjustment to professional and general liability (“PLGL”) reserves, which is partially offset by a benefit of $26.1 million related to the Florida supplemental payment program and provider tax adjustments.

●

Operating cash flows were $162.1 million compared to $133.5 million in the prior-year period and capital expenditures were $38.6 million compared to $167.7 million in the prior-year period

●

Added 240 licensed beds during the second quarter from newly constructed facilities

Adjusted net income attributable to Acadia, Adjusted EBITDA and Adjusted earnings per diluted share are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 10.

“Acadia delivered solid results in the second quarter that were driven by our continued focus on disciplined operational execution and providing quality care for our patients,” said Debbie Osteen, Chief Executive Officer of Acadia. “We made significant progress on our key priorities during the second quarter, including opening two new facilities with JV partners, continuing to ramp occupancy at our new facilities opened over the last few years, and generating strong free cash flow. We are well-positioned for additional progress in the second half of the year as we build upon our leadership position in the behavioral healthcare industry and continue expanding access to quality care for our patients.”

1 Calculated as (A)/(B) minus 1, where (A) equals total revenue in the second quarter of 2026 of $865.8 million minus $22.3 million of revenue from the Florida supplement payment program related to prior periods, and (B) equals total revenue in the second quarter of 2025 of $869.2 million minus $48.7 million of revenue from the Tennessee supplemental payment program for prior periods

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 2

July 28, 2026

Second Quarter Financial Summary

(dollars in millions, except per share amounts)

2026

2025

Change (%)

Acute Inpatient Psychiatric Facilities

494.6

495.4

Specialty Treatment Facilities

133.5

145.8

Comprehensive Treatment Facilities

141.2

141.5

Residential Treatment Facilities

96.5

86.5

Total Revenue

865.8

869.2

Reported Net Income

10.9

30.1

(64

Adjusted EBITDA

149.2

201.8

(26

Reported EPS

0.12

0.33

(64

Adjusted EPS

0.38

0.83

(54

Discussion of Second Quarter Results

Total revenue in the second quarter was $865.8 million, which was approximately flat compared with the prior-year period. Second quarter revenue includes $22.3 million from the Florida supplemental payment program related to the state fiscal year ended September 30, 2025. The second quarter of 2025 included $48.7 million of revenue from the Tennessee supplemental payment program for prior periods. Total revenue growth in the second quarter was 2.8% after normalizing for prior period supplemental payment program revenue in each of the respective quarters. Additionally, closed facilities represented a 1.4% negative impact to reported revenue growth in the second quarter.

Same-facility revenue in the second quarter was flat compared with the prior-year period. Same-facility patient days increased 0.8%, and same-facility revenue per patient day decreased 0.8%. The decline in same-facility revenue per patient day was driven by the timing of supplemental payment revenue in certain states. After normalizing for the impact of the timing of supplemental payment revenue related to prior periods in Florida and Tennessee, same-facility revenue growth would have been 3.2% compared with the prior-year period.

Acute inpatient psychiatric facility (“Acute”) revenue was $494.6 million, which was flat compared with the prior-year period. After normalizing for the impact of supplemental payment revenue related to prior periods in Florida and Tennessee, Acute revenue increased 5.7% in the second quarter compared to the prior-year period. Second quarter Acute inpatient volumes increased 5.5% compared with the prior-year period, driven primarily by expanded capacity from both newly constructed and existing facilities.

2 Calculated as (A)/(B) minus 1, where (A) equals total revenue in the second quarter of 2026 of $865.8 million minus $22.3 million of revenue from the Florida supplement payment program related to prior periods, and (B) equals total revenue in the second quarter of 2025 of $869.2 million minus $48.7 million of revenue from the Tennessee supplemental payment program for prior periods

3 Calculated as (A)/(B) minus 1, where (A) equals same-facility revenue in the second quarter of 2026 of $856.4 million minus $22.3 million of revenue from the Florida supplement payment program related to prior periods, and (B) equals same same-facility revenue in the second quarter of 2025 of $856.8 million minus $48.7 million of revenue from the Tennessee supplemental payment program for prior periods

4 Calculated as (A)/(B) minus 1, where (A) equals Acute revenue in the second quarter of 2026 of $494.6 million minus $22.3 million of revenue from the Florida supplement payment program related to prior periods, and (B) equals Acute revenue in the second quarter of 2025 of $495.4 million minus $48.7 million of revenue from the Tennessee supplemental payment program for prior periods

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 3

July 28, 2026

Specialty treatment facility revenue was $133.5 million, a decrease of 8.4% compared with the prior-year period. The revenue decline was related to Specialty facilities in Pennsylvania and the impact from having closed several Specialty facilities after the second quarter of 2025.

Comprehensive treatment facility (“CTC”) revenue was $141.2 million, which was flat compared with the prior-year period. Residential treatment facility (“RTC”) revenue was $96.5 million, an increase of 11.6% compared with the prior-year period.

Total operating expenses were $727.6 million in the second quarter of 2026, an increase of 7.3% compared with the prior-year period. Total operating expenses for the second quarter of 2026 include a $28.6 million adjustment to PLGL reserves for expected settlements of certain claims from the 2025 policy year. Excluding the $28.6 million adjustment to PLGL reserves, total operating expenses increased by 3.1% compared with the prior-year period.

Salaries, wages and benefits were $474.1 million for the second quarter of 2026, an increase of 4.8% compared with the prior-year period. The increase is primarily due to new facility openings as well as routine annual wage increases. Same-facility salaries, wages and benefits increased by 4.4%.

Adjusted EBITDA for the second quarter was $149.2 million, compared with $201.8 million in the prior-year period. The decline in Adjusted EBITDA compared with the prior-year period was primarily driven by a $39.3 million increase in PLGL costs, which includes the $28.6 million adjustment to the Company’s reserve for PLGL costs, and by the timing of supplemental payments related to prior periods in certain states. Second quarter Adjusted EBITDA includes a $26.1 million benefit related to the Florida supplemental payment program and provider tax adjustments, compared to a $39.5 million benefit in the second quarter of 2025 from the Tennessee supplemental payment program related to prior periods.

Development Activity

In June, the Company opened a 144-bed joint venture facility with Orlando Health in Florida, and a 96-bed joint venture facility with Methodist Jennie Edmundson Hospital in Iowa. In addition to the 240 beds added from these new facilities, the Company also opened two new CTC locations during the second quarter.

Cash and Liquidity

As of June 30, 2026, the Company had $171.3 million in cash and cash equivalents and $669.8 million available under its $1.0 billion revolving credit facility. As of June 30, 2026, Acadia’s net leverage ratio was 4.1x Adjusted EBITDA, calculated in accordance with its Credit Agreement as disclosed in the Company’s latest periodic reports and other filings with the Securities and Exchange Commission (“SEC”).

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 4

July 28, 2026

2026 Financial Guidance

Acadia today updated its financial guidance for 2026, as follows:

Full Year 2026

July Guidance Range

Full Year 2026

April Guidance Range

Revenue

$3.40 to $3.45 billion

$3.37 to $3.45 billion

Adjusted EBITDA

$590 to $615 million

$580 to $615 million

Adjusted earnings per diluted share

$1.45 to $1.60

$1.35 to $1.60

Operating Cash Flow

$350 to $400 million

$285 to $325 million

Capital expenditures

$235 to $255 million

$255 to $280 million

The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.

Conference Call

Acadia will hold a conference call to discuss its second quarter financial results at 8:00 a.m. Central Time / 9:00 a.m. Eastern Time on Wednesday, July 29, 2026. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The archived webcast will be available after the call has ended.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States (the “U.S.”). As of June 30, 2026, Acadia operated a network of 279 behavioral healthcare facilities with approximately 12,600 beds in 40 states and Puerto Rico. With approximately 25,000 employees serving more than 84,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, RTCs and outpatient clinics.

Description of Business

Unless the context otherwise requires, all references herein to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries own and operate acute inpatient psychiatric facilities, specialty treatment facilities, CTCs, RTCs and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the U.S. and Puerto Rico. The terms “facilities,” “centers,” “clinics,” and “hospitals” refer to entities owned, operated, or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to “employees” refer to employees of subsidiaries of Acadia Healthcare Company, Inc.

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 5

July 28, 2026

Forward-Looking Information

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements related to our strategy, growth and anticipated operating results for future periods. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties, and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (the “OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) changes in expectations resulting from actuarial and other reviews of the Company’s liability reserves and other aspects of its business; (vii) potential disruptions to our information technology systems or adverse impacts of a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to the OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 6

July 28, 2026

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(In thousands, except per share amounts)

Revenue

865,839

869,232

1,694,641

1,639,737

Salaries, wages and benefits (including equity-based compensation expense of $10,990, $10,549, $18,946 and $19,226, respectively)

474,095

452,417

941,135

897,688

Professional fees

55,760

49,961

108,957

95,668

Supplies

30,197

28,532

59,688

56,874

Rents and leases

11,844

12,610

23,577

24,266

Other operating expenses

155,747

134,414

286,826

248,416

Depreciation and amortization

50,427

48,995

102,853

96,027

Interest expense, net

38,178

35,138

76,508

64,320

Debt extinguishment costs

—

1,269

Legal settlements expense

—

13,751

3,504

Loss on impairment

7,364

1,452

7,364

1,452

Gain on sale of property, net

(2,359

)

(8,715

)

(3,581

)

(8,715

)

Transaction, legal and other costs

22,579

64,425

44,592

95,497

Total expenses

843,832

819,229

1,661,670

1,576,266

Income before income taxes

22,007

50,003

32,971

63,471

Provision for income taxes

9,747

12,067

16,247

16,471

Net income

12,260

37,936

16,724

47,000

Net income attributable to noncontrolling interests

(1,332

)

(7,809

)

(1,691

)

(8,499

)

Net income attributable to Acadia Healthcare Company, Inc.

10,928

30,127

15,033

38,501

Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:

Basic

0.12

0.33

0.17

0.42

Diluted

0.12

0.33

0.16

0.42

Weighted-average shares outstanding:

Basic

90,817

90,328

90,675

90,987

Diluted

91,374

90,435

91,205

91,400

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 7

July 28, 2026

Acadia Healthcare Company, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

June 30,

December 31,

2026

2025

(In thousands)

ASSETS

Current assets:

Cash and cash equivalents

171,290

133,242

Accounts receivable, net

470,750

440,604

Other current assets

203,247

240,293

Total current assets

845,287

814,139

Property and equipment, net

3,089,801

3,111,212

Goodwill

1,303,272

1,296,342

Intangible assets, net

100,186

96,672

Deferred tax assets

2,457

2,528

Operating lease right-of-use assets

138,923

134,005

Other assets

66,399

72,550

Total assets

5,546,325

5,527,448

LIABILITIES AND EQUITY

Current liabilities:

Current portion of long-term debt

32,500

28,438

Accounts payable

135,258

150,403

Accrued salaries and benefits

177,525

188,638

Current portion of operating lease liabilities

20,755

21,160

Other accrued liabilities

171,541

136,555

Total current liabilities

537,579

525,194

Long-term debt

2,382,069

2,471,529

Deferred tax liabilities

87,137

66,605

Operating lease liabilities

128,851

121,961

Other liabilities

218,842

201,607

Total liabilities

3,354,478

3,386,896

Redeemable noncontrolling interests

212,725

191,592

Equity:

Common stock

909

905

Additional paid-in capital

2,729,021

2,713,896

Accumulated deficit

(750,808

)

(765,841

)

Total equity

1,979,122

1,948,960

Total liabilities and equity

5,546,325

5,527,448

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 8

July 28, 2026

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Six Months Ended June 30,

2026

2025

(In thousands)

Operating activities:

Net income

16,724

47,000

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

102,853

96,027

Amortization of debt issuance costs

2,517

2,278

Equity-based compensation expense

18,946

19,226

Deferred income taxes

20,604

(8,753

)

Debt extinguishment costs

—

1,269

Non-cash legal settlements expense

—

3,504

Loss on impairment

7,364

1,452

Gain on sale of property, net

(3,581

)

(8,715

)

Other

516

1,128

Change in operating assets and liabilities, net of effect of acquisitions:

Accounts receivable, net

(30,146

)

(42,660

)

Other current assets

30,356

(3,797

)

Other assets

(572

)

(7,684

)

Accounts payable and other accrued liabilities

36,195

27,684

Accrued salaries and benefits

(16,631

)

(3,940

)

Other liabilities

38,453

20,962

Net cash provided by operating activities

223,598

144,981

Investing activities:

Cash paid for acquisitions, net of cash acquired

—

(8,165

)

Cash paid for capital expenditures

(115,117

)

(342,378

)

Proceeds from sale of property and equipment

26,497

16,623

Other

(4,270

)

(101

)

Net cash used in investing activities

(92,890

)

(334,021

)

Financing activities:

Borrowings on long-term debt

—

1,200,000

Borrowings on revolving credit facility

85,000

830,000

Principal payments on revolving credit facility

(160,000

)

(1,035,000

)

Principal payments on long-term debt

(12,188

)

(4,063

)

Repayment of long-term debt

—

(670,856

)

Payment of debt issuance costs

—

(18,615

)

Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises

(3,807

)

(3,716

)

Repurchase of common stock

—

(50,034

)

Contributions from noncontrolling partners in joint ventures

990

—

Distributions to noncontrolling partners in joint ventures

(2,593

)

(1,990

)

Cash paid for contingent consideration

—

(1,500

)

Other

(62

)

(70

)

Net cash (used in) provided by financing activities

(92,660

)

244,156

Net increase in cash and cash equivalents

38,048

55,116

Cash and cash equivalents at beginning of the period

133,242

76,305

Cash and cash equivalents at end of the period

171,290

131,421

Effect of acquisitions:

Assets acquired, excluding cash

20,760

19,881

Liabilities assumed

—

(842

)

Redeemable noncontrolling interest resulting from an acquisition

(20,760

)

(10,874

)

Cash paid for acquisitions, net of cash acquired

—

8,165

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 9

July 28, 2026

Acadia Healthcare Company, Inc.

Operating Statistics (1)

(Unaudited, $ in thousands except per Patient Day metrics)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

% Change

2026

2025

% Change

Same Facility Results (2)

Revenue

856,354

856,797

-0.1

1,669,738

1,615,143

3.4

Patient Days

794,177

787,930

0.8

1,567,035

1,548,594

1.2

Admissions

54,141

50,880

6.4

106,100

99,656

6.5

Average Length of Stay (3)

14.7

15.5

-5.3

14.8

15.5

-5.0

Revenue per Patient Day

1,078

1,087

-0.8

1,066

1,043

2.2

Adjusted EBITDA

200,937

245,571

-18.2

400,427

424,020

-5.6

Total Facility Results

Revenue

865,839

869,232

-0.4

1,694,641

1,639,737

3.3

Patient Days

804,970

804,840

0.0

1,591,750

1,579,773

0.8

Admissions

55,173

51,922

6.3

108,731

101,605

7.0

Average Length of Stay (3)

14.6

15.5

-5.9

14.6

15.5

-5.8

Revenue per Patient Day

1,076

1,080

-0.4

1,065

1,038

2.6

Adjusted EBITDA

187,677

240,397

-21.9

373,166

412,758

-9.6

(1) Total facility and same facility results may not be indicative of the overall performance of our business and should not be considered as alternatives for net income or any other performance measures in accordance with GAAP (as defined herein).

(2) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services.

(3) Average length of stay is defined as patient days divided by admissions.

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 10

July 28, 2026

Acadia Healthcare Company, Inc.

Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA and

Same Facility Adjusted EBITDA

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(in thousands)

Net income attributable to Acadia Healthcare Company, Inc.

10,928

30,127

15,033

38,501

Net income attributable to noncontrolling interests

1,332

7,809

1,691

8,499

Provision for income taxes

9,747

12,067

16,247

16,471

Interest expense, net

38,178

35,138

76,508

64,320

Depreciation and amortization

50,427

48,995

102,853

96,027

EBITDA

110,612

134,136

212,332

223,818

Adjustments:

Equity-based compensation expense (a)

10,990

10,549

18,946

19,226

Transaction, legal and other costs (b)

22,579

64,425

44,592

95,497

Debt extinguishment costs (c)

—

1,269

Legal settlements expense (d)

—

13,751

3,504

Loss on impairment (e)

7,364

1,452

7,364

1,452

Gain on sale of property, net (f)

(2,359

)

(8,715

)

(3,581

)

(8,715

)

Adjusted EBITDA

149,186

201,847

293,404

336,051

Corporate general and administrative costs (g)

(38,491

)

(38,550

)

(79,762

)

(76,707

)

Total Facility Adjusted EBITDA

187,677

240,397

373,166

412,758

De novos, acquisitions, and closed facilities (h)

(13,260

)

(5,174

)

(27,261

)

(11,262

)

Same Facility Adjusted EBITDA

200,937

245,571

400,427

424,020

See footnotes on pages 11-12.

Acadia Healthcare Company, Inc.

Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to

Adjusted Income Attributable to Acadia Healthcare Company, Inc.

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(in thousands, except per share amounts)

Net income attributable to Acadia Healthcare Company, Inc.

10,928

30,127

15,033

38,501

Adjustments to income:

Transaction, legal and other costs (b)

22,579

64,425

44,592

95,497

Debt extinguishment costs (c)

—

1,269

Legal settlements expense (d)

—

13,751

3,504

Loss on impairment (e)

7,364

1,452

7,364

1,452

Gain on sale of property, net (f)

(2,359

)

(8,715

)

(3,581

)

(8,715

)

Provision for income taxes

9,747

12,067

16,247

16,471

Adjusted income before income taxes attributable to

Acadia Healthcare Company, Inc.

48,259

99,356

93,406

147,979

Income tax effect of adjustments to income (i)

13,190

24,516

25,014

36,210

Adjusted income attributable to Acadia Healthcare Company, Inc.

35,069

74,840

68,392

111,769

Weighted-average shares outstanding - diluted

91,374

90,435

91,205

91,400

Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share

0.38

0.83

0.75

1.22

See footnotes on pages 11-12.

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 11

July 28, 2026

Acadia Healthcare Company, Inc.

Footnotes

We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows:

• EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization.

• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, debt extinguishment costs, legal settlements expense, loss on impairment and gain on sale of property, net.

• Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, debt extinguishment costs, legal settlements expense, loss on impairment, gain on sale of property, net, and provision for income taxes.

• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.

• Total facility adjusted EBITDA: Adjusted EBITDA adjusted for general and administrative costs related to our corporate functions. General and administrative costs directly related to the facilities are included in total facility results.

• Same facility adjusted EBITDA: Adjusted EBITDA for facilities and services to those facilities operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired, divested or removed from service during the current or prior year.

The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

Total facility results include operating results for all of our facilities and services but exclude general and administrative costs related to our corporate functions. Such costs related to our corporate functions include, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. General and administrative costs directly related to the facilities are included in facility results. Such costs directly related to our facilities include, amongst others, labor at the facility level, insurance, including property, professional, legal and general liability insurance, hospital supplies, including medication, utilities and food service, and general maintenance costs for the facility. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Note that total facility costs include those related to new facilities and the cost of closure and run-out costs related to facilities we have closed. We believe that providing results on a total facility basis is helpful to our investors as a measure of our financial and operating performance because it neutralizes the impact of corporate-level items that do not arise out of our core operations at our facilities.

Same facility results include operating results only for facilities and services operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired during the current or prior year, as well as facilities divested or removed from service. We believe that providing results on a same facility basis is helpful to investors because it neutralizes the impact of new facilities that are in early stages of operation and facilities that we no longer operate, each of which may distort investors’ understanding of the Company’s underlying performance at our existing and continuing facilities. Further, we believe that providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. For these reasons, we believe that same facility results are particularly useful during periods of significant expansion or contraction.

Total facility results reflect adjustments that are intended to provide the specific presentation described above, and same facility results reflect adjustments that may be irregular in timing from period to period related to newly opened or acquired facilities or facilities that we no longer operate, and may omit certain results that investors may view as important. Total facility and same facility results may therefore not be indicative of the overall performance of our business and should be not be considered as alternatives for net income or any other performance measures derived in accordance with GAAP.

The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses.

- MORE -

ACHC Announces Second Quarter 2026 Results

Page 12

July 28, 2026

Acadia Healthcare Company, Inc.

Footnotes (continued)

(a) Represents the equity-based compensation expense of Acadia. Equity-based compensation expense is excluded from Adjusted EBITDA because we believe that the cost of equity awards granted to employees does not contribute to the earnings potentially available for distributions to Acadia's equity holders or reinvestment into the Company's business.

(b) Represents transaction, legal, and other costs incurred by Acadia primarily related to the following categories: (1) government investigations; (2) termination and restructuring costs; (3) legal, accounting, and other acquisition-related costs; and (4) management transition costs. Government investigations include legal fees and settlement costs related to certain litigation. Termination and restructuring costs include costs, net of gains, incurred related to workforce reductions, contract amendments, and the closure and disposition of certain facilities, including related lease terminations. Legal, accounting and other acquisition-related costs include costs incurred for the development of new facilities ($0.2 million and $0.3 million for the three and six months ended June 30, 2026, respectively, and $0.4 million and $1.3 million for the three and six months ended June 30, 2025, respectively) and legal and settlement costs incurred related to certain litigation not included in government investigations ($9.1 million and $9.7 million for the three and six months ended June 30, 2026, respectively, and $0.4 million and $(2.6) million for the three and six months ended June 30, 2025, respectively). Management transition costs consist primarily of severance benefits incurred with the departure of the Company’s former Chief Executive Officer, Christopher H. Hunter. The table below quantifies each of the components of transaction, legal and other costs for the periods presented. Such transaction, legal and other costs are excluded from Adjusted EBITDA because we believe that the nature, size, and number of these costs can vary dramatically from period to period and between Acadia and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(in thousands)

Government investigations

7,471

53,526

19,893

84,538

Termination and restructuring costs

5,784

10,074

10,746

12,239

Legal, accounting and other acquisition-related costs

9,324

825

10,040

(1,280

)

Management transition costs

—

3,913

—

Transaction, legal, and other costs

22,579

64,425

44,592

95,497

(c) Represents debt extinguishment costs recorded during the first quarter of 2025 in connection with the refinancing of the prior credit facility. Debt extinguishment is excluded from Adjusted EBITDA because we believe that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.

(d) Represents legal settlements expense in excess of the Company's primary and excess insurance policies. Legal settlements expense for the six months ended June 30, 2026, relates to costs associated with the settlement of Sandoval v. Acadia Healthcare Company, Inc., Marin County Super. Ct. No. CIV1802171. Legal settlements expense for the six months ended June 30, 2025, relates to costs associated with the Desert Hills litigation. Legal settlements expense is excluded from Adjusted EBITDA because we believe that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.

(e) Represents non-cash impairment charges. Non-cash impairment charges are excluded from Adjusted EBITDA because we believe that these charges are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.

(f) Represents gain on facility property sales, net. Net gains from facility property sales are excluded from Adjusted EBITDA because we believe that these gains are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results.

(g) Represents general and administrative costs related to our corporate functions, including, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Corporate general and administrative costs are excluded to present Total Facility Adjusted EBITDA because we believe that providing results on a total facility basis is helpful to our investors as a measure of the financial and operating performance of our core operations at our facilities.

(h) Represents the portion of EBITDA for the periods presented attributable to de novos and acquired facilities in operation for less than one year and facilities closed during such period. De novos are newly developed facilities built by Acadia or with a joint venture partner. Such amounts are excluded from Adjusted EBITDA to present Same Facility Adjusted EBITDA because we believe providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities.

(i) Represents the income tax effect of adjustments to income based on tax rates of 27.3% and 24.7% for the three months ended June 30, 2026 and 2025, respectively, and 26.8% and 24.5% for the six months ended June 30, 2026 and 2025, respectively. We believe excluding the income tax effect of adjustments to income assists investors in understanding the tax provision associated with those adjustments and the effect on net income.

Investor Contact:

investorrelations@acadiahealthcare.com

- MORE -

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: ex_994475_source.htm · Sequence: 3

Image Exhibit

Exhibit 99.2

GRAPHIC

Filename: a01.jpg · Sequence: 8

Binary file (145223 bytes)

Download a01.jpg

GRAPHIC

Filename: a02.jpg · Sequence: 9

Binary file (205282 bytes)

Download a02.jpg

GRAPHIC

Filename: a03.jpg · Sequence: 10

Binary file (93260 bytes)

Download a03.jpg

GRAPHIC

Filename: a04.jpg · Sequence: 11

Binary file (45439 bytes)

Download a04.jpg

GRAPHIC

Filename: a05.jpg · Sequence: 12

Binary file (61456 bytes)

Download a05.jpg

GRAPHIC

Filename: a06.jpg · Sequence: 13

Binary file (60361 bytes)

Download a06.jpg

GRAPHIC

Filename: a07.jpg · Sequence: 14

Binary file (45936 bytes)

Download a07.jpg

GRAPHIC

Filename: a08.jpg · Sequence: 15

Binary file (46300 bytes)

Download a08.jpg

GRAPHIC

Filename: a09.jpg · Sequence: 16

Binary file (84433 bytes)

Download a09.jpg

GRAPHIC

Filename: a10.jpg · Sequence: 17

Binary file (65885 bytes)

Download a10.jpg

GRAPHIC

Filename: a11.jpg · Sequence: 18

Binary file (61649 bytes)

Download a11.jpg

GRAPHIC

Filename: a12.jpg · Sequence: 19

Binary file (50574 bytes)

Download a12.jpg

GRAPHIC

Filename: a13.jpg · Sequence: 20

Binary file (60070 bytes)

Download a13.jpg

GRAPHIC

Filename: a14.jpg · Sequence: 21

Binary file (21419 bytes)

Download a14.jpg

GRAPHIC

Filename: a15.jpg · Sequence: 22

Binary file (48256 bytes)

Download a15.jpg

GRAPHIC

Filename: a16.jpg · Sequence: 23

Binary file (70096 bytes)

Download a16.jpg

GRAPHIC

Filename: a17.jpg · Sequence: 24

Binary file (64960 bytes)

Download a17.jpg

GRAPHIC

Filename: a18.jpg · Sequence: 25

Binary file (138898 bytes)

Download a18.jpg

GRAPHIC

Filename: a19.jpg · Sequence: 26

Binary file (136411 bytes)

Download a19.jpg

GRAPHIC

Filename: a20.jpg · Sequence: 27

Binary file (122490 bytes)

Download a20.jpg

GRAPHIC

Filename: a21.jpg · Sequence: 28

Binary file (128754 bytes)

Download a21.jpg

GRAPHIC

Filename: acadialogo01.jpg · Sequence: 29

Binary file (10139 bytes)

Download acadialogo01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 31

v3.26.1

Document And Entity Information

Jul. 28, 2026

Document Information [Line Items]

Entity, Registrant Name

Acadia Healthcare Company, Inc.

Document, Type

8-K

Document, Period End Date

Jul. 28, 2026

Entity, Incorporation, State or Country Code

Entity, File Number

001-35331

Entity, Tax Identification Number

45-2492228

Entity, Address, Address Line One

4020 Aspen Grove Drive, Suite 900

Entity, Address, City or Town

Franklin

Entity, Address, State or Province

Entity, Address, Postal Zip Code

37067

City Area Code

615

Local Phone Number

861-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

ACHC

Security Exchange Name

NASDAQ

Entity, Emerging Growth Company

false

Amendment Flag

false

Entity, Central Index Key

0001520697

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration